24-Week Interim Findings from a Randomized Phase 2 Study of Iptacopan (LNP023) Indicate High Remission Rates in Participants with Active ANCA-Associated Vasculitis (ACR Convergence 2026) - Oct 16, 2026 - Abstract #LB16; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; No abstract available
Clinical • Late-breaking abstract • P2 data • ANCA Vasculitis • Vasculitis
|